Format

Send to

Choose Destination
Cancer Res. 2014 Jul 15;74(14):3913-22. doi: 10.1158/0008-5472.CAN-14-0247. Epub 2014 May 8.

Say no to DMSO: dimethylsulfoxide inactivates cisplatin, carboplatin, and other platinum complexes.

Author information

1
Authors' Affiliations: Laboratory of Cell Biology, Center for Cancer Research, National Cancer Institute;
2
Advanced Mass Spectrometry Facility, National Institute of Diabetes & Digestive & Kidney Diseases, NIH, Bethesda;
3
Division of Preclinical Innovation, National Institutes of Health Chemical Genomics Center, National Center for Advancing Translational Sciences, NIH, Rockville, Maryland; and.
4
Department of Chemistry, Eastern Michigan University, Ypsilanti, Michigan.
5
Authors' Affiliations: Laboratory of Cell Biology, Center for Cancer Research, National Cancer Institute; gottesmm@mail.nih.gov.

Abstract

The platinum drugs cisplatin, carboplatin, and oxaliplatin are highly utilized in the clinic and as a consequence are extensively studied in the laboratory setting. In this study, we examined the literature and found a significant number of studies (11%-34%) in prominent cancer journals utilizing cisplatin dissolved in DMSO. However, dissolving cisplatin in DMSO for laboratory-based studies results in ligand displacement and changes to the structure of the complex. We examined the effect of DMSO on platinum complexes, including cisplatin, carboplatin, and oxaliplatin, finding that DMSO reacted with the complexes, inhibited their cytotoxicity and their ability to initiate cell death. These results render a substantial portion of the literature on cisplatin uninterpretable. Raising awareness of this significant issue in the cancer biology community is critical, and we make recommendations on appropriate solvation of platinum drugs for research.

PMID:
24812268
PMCID:
PMC4153432
DOI:
10.1158/0008-5472.CAN-14-0247
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center